Aurora Spine Launches New Biologics Portfolio
Aurora Spine (OTCQB: ASAPF) launched Aurora Biologics on Oct 27, 2025, creating a vertically integrated biologics division to pair with its interspinous, lumbar, and sacroiliac implant systems such as ZIP™, Hydra A.E.R.O.™, DEXA™, and SiLO™.
The new line includes TURBO FUSE™ Fiber Putty, OSTEO GRAFT™ DBM Putty, and OSTEO BRIDGE™ Sponge Strips, all formulated from 100% allograft bone without synthetic carriers to support osteoconduction and osteoinduction. Management said the platform is designed to improve fusion outcomes, surgical efficiency, and long-term fusion integrity and projected a more than 30% increase over prior biologic offerings.
Aurora Spine (OTCQB: ASAPF) ha lanciato Aurora Biologics il 27 ottobre 2025, creando una divisione di biologics verticalmente integrata per accompagnare i suoi sistemi di impianti interspinici, lombari e sacroiliaci come ZIP™, Hydra A.E.R.O.™, DEXA™, e SiLO™.
La nuova linea include TURBO FUSE™ Fiber Putty, OSTEO GRAFT™ DBM Putty, e OSTEO BRIDGE™ Sponge Strips, tutti formulati a partire da ossobore allograft al 100% senza portatori sintetici per supportare l'osteoconduttiva e l'osteoinduzione. La direzione ha detto che la piattaforma è progettata per migliorare gli esiti di fusione, l'efficienza chirurgica e l'integrità della fusione a lungo termine e prevede un aumento superiore al 30% rispetto alle offerte biologiche precedenti.
Aurora Spine (OTCQB: ASAPF) lanzó Aurora Biologics el 27 de octubre de 2025, creando una división de biológicos verticalmente integrada para emparejarse con sus sistemas de implantes interespinosos, lumbares y sacroilíacos como ZIP™, Hydra A.E.R.O.™, DEXA™ y SiLO™.
La nueva línea incluye TURBO FUSE™ Fiber Putty, OSTEO GRAFT™ DBM Putty, y OSTEO BRIDGE™ Sponge Strips, todos formulados a partir de hueso de donante al 100% sin portadores sintéticos para apoyar la osteoconducción y la osteoinducción. La dirección dijo que la plataforma está diseñada para mejorar los resultados de fusión, la eficiencia quirúrgica y la integridad de la fusión a largo plazo y proyectó un aumento de más del 30% sobre las ofertas biológicas anteriores.
Aurora Spine (OTCQB: ASAPF)는 Aurora Biologics를 2025년 10월 27일에 출시하여 ZIP™, Hydra A.E.R.O.™, DEXA™, SiLO™ 등의 척추 사이 간극, 요부, 천골-장골 임플란트 시스템과 결합하기 위한 수직적으로 통합된 바이오제너틱스 부서를 만들었습니다.
새로운 라인에는 TURBO FUSE™ Fiber Putty, OSTEO GRAFT™ DBM Putty, 및 OSTEO BRIDGE™ Sponge Strips가 포함되며, 모두 합성 운반체 없이 100% 동종골로 구성되어 골화 촉진 및 골형성 유도를 지원합니다. 경영진은 이 플랫폼이 융합 결과, 수술 효율성, 그리고 장기적인 융합 무결성을 개선하도록 설계되었으며 이전 생물학적 제품 대비 30% 이상 증가를 예상한다고 밝혔습니다.
Aurora Spine (OTCQB: ASAPF) a lancé Aurora Biologics le 27 octobre 2025, créant une division de biologiques verticalement intégrée pour accompagner ses systèmes d'implants interépineux, lombaires et sacro-iliaques tels que ZIP™, Hydra A.E.R.O.™, DEXA™, et SiLO™.
La nouvelle gamme comprend TURBO FUSE™ Fiber Putty, OSTEO GRAFT™ DBM Putty, et OSTEO BRIDGE™ Sponge Strips, tous formulés à partir d'ossein allogénique à 100% sans porteurs synthétiques pour soutenir l'ostéoconduction et l'ostéoinduction. La direction a déclaré que la plateforme est conçue pour améliorer les résultats de fusion, l'efficacité chirurgicale et l'intégrité de la fusion à long terme et prévoit une augmentation de plus de 30% par rapport aux offres biologiques précédentes.
Aurora Spine (OTCQB: ASAPF) führte Aurora Biologics am 27. Oktober 2025 ein und schuf eine vertikal integrierte Biologics-Sparte, um sie mit den interspinösen, lumbalen und sakroiliakalen Implantatsystemen wie ZIP™, Hydra A.E.R.O.™, DEXA™ und SiLO™ zu verbinden.
Die neue Produktlinie umfasst TURBO FUSE™ Fiber Putty, OSTEO GRAFT™ DBM Putty und OSTEO BRIDGE™ Sponge Strips, die alle aus 100% Allograft-Knochen bestehen, ohne synthetische Träger, um Osteokonduktion und Osteoinduktion zu unterstützen. Das Management sagte, dass die Plattform darauf ausgelegt ist, die Fusionsergebnisse, die chirurgische Effizienz und die langfristige Fusionierte Integrität zu verbessern, und prognostizierte eine mehr als 30%-ige Steigerung gegenüber früheren biologischen Angeboten.
Aurora Spine (OTCQB: ASAPF) أطلقت Aurora Biologics في 27 أكتوبر 2025، مما أنشأ قسمًا بيولوجيًا مدمجًا رأسياً ليتناسب مع أنظمة الزرع بين الفقرات، وأسفل الظهر، والجزء العجزي الحرقفي مثل ZIP™ و Hydra A.E.R.O.™ و DEXA™ و SiLO™.
تشمل الخط الجديد TURBO FUSE™ Fiber Putty، OSTEO GRAFT™ DBM Putty، و OSTEO BRIDGE™ Sponge Strips، جميعها مصاغة من عظم متبرع به بنسبة 100% بدون حوامل صناعية لدعم التكون العظمي والتكوّن العظمي المحفز. قالت الإدارة إن المنصة مصممة لتحسين نتائج الالتحام، وكفاءة الجراحة، وسلامة الالتحام على المدى الطويل وتوقعت زيادة تفوق 30% على العروض البيولوجية السابقة.
Aurora Spine (OTCQB: ASAPF) 于 2025年10月27日 推出 Aurora Biologics，创建了一个垂直整合的生物制剂部门，以与其椎间、腰椎和骶髂植入系统（如 ZIP™、Hydra A.E.R.O.™、DEXA™、SiLO™）搭配使用。
新系列包括 TURBO FUSE™ Fiber Putty、OSTEO GRAFT™ DBM Putty、和 OSTEO BRIDGE™ Sponge Strips，全部由 100% 同种异体骨制成，且不含合成载体，以支持成骨扩散与诱导。管理层表示，该平台旨在提高手术融合结果、提高手术效率以及长期融合完整性，并预计比此前的生物制剂产品提升 超过30% 。
- Aurora Biologics launch dated Oct 27, 2025
- Portfolio includes 3 named allograft products
- Products use 100% allograft with no synthetic carriers
- Company projects >30% increase over prior biologic offerings
- None.
New Aurora Biologics Division Establishes Aurora Spine as a Vertically Integrated Source for Spinal Implants and Biologics
CARLSBAD, CA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine”) (TSXV: ASG) (OTCQB: ASAPF), a leader in minimally invasive spine and interventional pain solutions, today announced the launch of Aurora Biologics, a new division dedicated to advancing spinal fusion success through best-in-class biologic innovation.
The establishment of Aurora Biologics creates seamless synergy across Aurora’s growing spine ecosystem—including its renowned interspinous, lumbar, and sacroiliac fusion systems such as ZIP™, Hydra A.E.R.O.™, DEXA™, and SiLO™ portfolios. These mechanical and regenerative technologies now converge within one integrated platform designed to enhance patient outcomes, improve surgical efficiency, and promote long-term fusion integrity.
Comprehensive Biologic Solutions
Aurora Biologics launches with a complete suite of allograft solutions, including:
- TURBO FUSE™ Fiber Putty – a bone graft substitute composed of demineralized bone fibers that increase surface area and promote cellular attachment.
- OSTEO GRAFT™ DBM Putty – a demineralized cortical bone graft with a cohesive, moldable consistency to support bone formation without synthetic carriers.
- OSTEO BRIDGE™ Sponge Strips – a sponge-like bone graft substitute that conforms to patient anatomy and fills bone voids to support structural regeneration.
Each biologic is formulated from 100 percent allograft bone, free of synthetic carriers, delivering natural osteoconductive and osteoinductive properties for predictable, high-quality bone growth. Fully moldable and cohesive, these materials are designed to fill bony defects or augment fusion sites, providing a natural biologic scaffold for bone regeneration.
Engineered to work synergistically with Aurora’s implant technologies, the Aurora Biologics line creates a comprehensive, biologically active fusion environment that optimizes outcomes for both patients and surgeons.
Executive Commentary
“Aurora Biologics completes our strategy of providing customers with a seamless, fully integrated portfolio,” said Mathew Goldstone, Chief Commercial Officer of Aurora Spine. “Each of our mechanical fusion systems—whether lumbar, SI, or cervical—is designed to promote bone growth. With the addition of Aurora Biologics, we now enhance the healing phase as well, allowing surgeons to deliver a fully optimized fusion procedure from start to finish.”
“Our new Aurora Biologics platform not only reinforces our commitment to improved clinical outcomes but also serves as a strong growth catalyst,” said Trent J. Northcutt, President & CEO of Aurora Spine. “By integrating biologics across our minimally invasive product portfolio, we anticipate more than a 30 percent increase over prior biologic offerings—driving stronger margins and creating a powerful new profit engine for Aurora Spine.”
Setting a New Standard in Spine Care
Aurora Spine believes the introduction of Aurora Biologics will set a new benchmark for biologic performance in spine care. True to the company’s philosophy of “Simplifying the Complex,” these products are designed to be best-in-class—easy to use, clinically effective, and backed by Aurora Spine’s unwavering commitment to innovation and quality.
About Aurora Spine
Aurora Spine Corporation (TSXV: ASG) (OTCQB: ASAPF) is an innovative designer and manufacturer of minimally invasive spinal implants and interventional pain management technologies. Headquartered in Carlsbad, California, the company’s mission is to improve spinal surgery outcomes through simplified, integrated, and cost-effective solutions that advance patient care worldwide.
Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains statements that constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). Forward-looking statements include, but are not limited to, statements regarding the expected performance, commercial success, or market adoption of the Aurora Biologics product line; anticipated revenue growth or margin improvements; and the company’s plans, objectives, expectations, or intentions.
Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, changes in regulatory environments, competitive conditions, demand for the company’s products, and other risks detailed from time to time in Aurora Spine’s public filings with securities regulators.
Readers are cautioned not to place undue reliance on forward-looking statements. Aurora Spine undertakes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws.
Company and investor Contacts
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
Phone: (760) 424-2004
Chad Clouse
Chief Financial Officer
Phone: (760) 424-2004
Website: www.aurora-spine.com
Investor Relations
Adam Lowensteiner
Lytham Partners
Phone: (646) 829-9702
Email: asapf@lythampartners.com
FAQ
What did Aurora Spine announce on October 27, 2025 regarding biologics (ASAPF)?
Which biologic products did Aurora Spine introduce with Aurora Biologics (ASAPF)?
Are Aurora Biologics products synthetic or natural for Aurora Spine (ASAPF)?
How will Aurora Biologics interact with Aurora Spine's implant portfolio (ASAPF)?
What financial or growth impact did Aurora Spine claim for Aurora Biologics (ASAPF)?
